vs
博士伦（BLCO）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Rollins, Inc.的1.6倍（$1.4B vs $906.4M），Rollins, Inc.净利率更高（11.9% vs -4.1%，领先16.0%），Rollins, Inc.同比增速更快（10.2% vs 9.8%），Rollins, Inc.自由现金流更多（$111.2M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs 0.8%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
BLCO vs ROL — 直观对比
营收规模更大
BLCO
是对方的1.6倍
$906.4M
营收增速更快
ROL
高出0.4%
9.8%
净利率更高
ROL
高出16.0%
-4.1%
自由现金流更多
ROL
多$51.2M
$60.0M
两年增速更快
BLCO
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $906.4M |
| 净利润 | $-58.0M | $107.8M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 16.1% |
| 净利率 | -4.1% | 11.9% |
| 营收同比 | 9.8% | 10.2% |
| 净利润同比 | -1833.3% | 2.5% |
| 每股收益（稀释后） | $-0.16 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.4B | $912.9M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.3B | $999.5M | ||
| Q1 25 | $1.1B | $822.5M | ||
| Q4 24 | $1.3B | $832.2M | ||
| Q3 24 | $1.2B | $916.3M | ||
| Q2 24 | $1.2B | $891.9M |
净利润BLCOROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-58.0M | $116.4M | ||
| Q3 25 | $-28.0M | $163.5M | ||
| Q2 25 | $-62.0M | $141.5M | ||
| Q1 25 | $-212.0M | $105.2M | ||
| Q4 24 | $-3.0M | $105.7M | ||
| Q3 24 | $4.0M | $136.9M | ||
| Q2 24 | $-151.0M | $129.4M |
营业利润率BLCOROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 8.0% | 17.5% | ||
| Q3 25 | 7.4% | 21.9% | ||
| Q2 25 | -0.9% | 19.8% | ||
| Q1 25 | -7.3% | 17.3% | ||
| Q4 24 | 6.8% | 18.1% | ||
| Q3 24 | 3.6% | 20.9% | ||
| Q2 24 | 2.1% | 20.4% |
净利率BLCOROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -4.1% | 12.8% | ||
| Q3 25 | -2.2% | 15.9% | ||
| Q2 25 | -4.9% | 14.2% | ||
| Q1 25 | -18.6% | 12.8% | ||
| Q4 24 | -0.2% | 12.7% | ||
| Q3 24 | 0.3% | 14.9% | ||
| Q2 24 | -12.4% | 14.5% |
每股收益（稀释后）BLCOROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-0.16 | $0.24 | ||
| Q3 25 | $-0.08 | $0.34 | ||
| Q2 25 | $-0.18 | $0.29 | ||
| Q1 25 | $-0.60 | $0.22 | ||
| Q4 24 | $-0.00 | $0.22 | ||
| Q3 24 | $0.01 | $0.28 | ||
| Q2 24 | $-0.43 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $116.5M |
| 总债务越低越好 | $5.0B | $650.6M |
| 股东权益账面价值 | $6.4B | $1.4B |
| 总资产 | $14.0B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资BLCOROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $383.0M | $100.0M | ||
| Q3 25 | $310.0M | $127.4M | ||
| Q2 25 | $266.0M | $123.0M | ||
| Q1 25 | $202.0M | $201.2M | ||
| Q4 24 | $305.0M | $89.6M | ||
| Q3 24 | $329.0M | $95.3M | ||
| Q2 24 | $285.0M | $106.7M |
总债务BLCOROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $5.0B | $486.1M | ||
| Q3 25 | $5.0B | $485.7M | ||
| Q2 25 | $5.0B | $485.3M | ||
| Q1 25 | $4.8B | $485.5M | ||
| Q4 24 | $4.8B | $395.3M | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益BLCOROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $6.4B | $1.4B | ||
| Q3 25 | $6.4B | $1.5B | ||
| Q2 25 | $6.4B | $1.4B | ||
| Q1 25 | $6.4B | $1.4B | ||
| Q4 24 | $6.5B | $1.3B | ||
| Q3 24 | $6.6B | $1.3B | ||
| Q2 24 | $6.5B | $1.2B |
总资产BLCOROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $14.0B | $3.1B | ||
| Q3 25 | $13.8B | $3.2B | ||
| Q2 25 | $13.8B | $3.2B | ||
| Q1 25 | $13.4B | $2.9B | ||
| Q4 24 | $13.5B | $2.8B | ||
| Q3 24 | $13.5B | $2.8B | ||
| Q2 24 | $13.3B | $2.8B |
负债/权益比BLCOROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.78× | 0.35× | ||
| Q3 25 | 0.77× | 0.32× | ||
| Q2 25 | 0.77× | 0.34× | ||
| Q1 25 | 0.76× | 0.36× | ||
| Q4 24 | 0.74× | 0.30× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $111.2M |
| 自由现金流率自由现金流/营收 | 4.3% | 12.3% |
| 资本支出强度资本支出/营收 | 5.4% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $621.1M |
8季度趋势，按日历期对齐
经营现金流BLCOROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $136.0M | $164.7M | ||
| Q3 25 | $137.0M | $191.3M | ||
| Q2 25 | $35.0M | $175.1M | ||
| Q1 25 | $-25.0M | $146.9M | ||
| Q4 24 | $22.0M | $188.2M | ||
| Q3 24 | $154.0M | $146.9M | ||
| Q2 24 | $15.0M | $145.1M |
自由现金流BLCOROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $60.0M | $159.0M | ||
| Q3 25 | $63.0M | $182.8M | ||
| Q2 25 | $-54.0M | $168.0M | ||
| Q1 25 | $-135.0M | $140.1M | ||
| Q4 24 | $-70.0M | $184.0M | ||
| Q3 24 | $94.0M | $139.4M | ||
| Q2 24 | $-57.0M | $136.4M |
自由现金流率BLCOROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 4.3% | 17.4% | ||
| Q3 25 | 4.9% | 17.8% | ||
| Q2 25 | -4.2% | 16.8% | ||
| Q1 25 | -11.9% | 17.0% | ||
| Q4 24 | -5.5% | 22.1% | ||
| Q3 24 | 7.9% | 15.2% | ||
| Q2 24 | -4.7% | 15.3% |
资本支出强度BLCOROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 5.4% | 0.6% | ||
| Q3 25 | 5.8% | 0.8% | ||
| Q2 25 | 7.0% | 0.7% | ||
| Q1 25 | 9.7% | 0.8% | ||
| Q4 24 | 7.2% | 0.5% | ||
| Q3 24 | 5.0% | 0.8% | ||
| Q2 24 | 5.9% | 1.0% |
现金转化率BLCOROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | 38.50× | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
ROL
暂无分部数据
